

Statin Therapy for Patients with Cardiovascular Disease

Topic	Explanation
Measure Type	Static Star Measure
Description of the Measure	Percentage of members with cardiovascular disease who had at least one dispensing event for a high or moderate intensity statin medication in the measurement year.
Eligible Population	<p>Male members aged 21–75 and females age 40–75 identified by event or diagnosis during the year prior to the measurement year who were:</p> <ul style="list-style-type: none"> • Discharged from an inpatient setting with myocardial infarction. • Had a CABG, PCI, or other revascularization procedure in any setting. • Diagnosed as having ischemic vascular disease during both the measurement year and the year prior. Criteria need not be the same across both years, but must meet the following: <ul style="list-style-type: none"> - At least one acute inpatient encounter with an IVD diagnosis. - At least one outpatient encounter with an IVD diagnosis, a telephone visit, e-visit, or virtual check-in with an IVD diagnosis. <p>Exclusions:</p> <ul style="list-style-type: none"> • Dispensed at least one prescription for clomiphene during the measurement year or year prior. • Cirrhosis in the measurement year or year prior. Most common codes to identify cirrhosis: K70.30, K70.31, K71.7, K74.3, K74.69 • Myalgia, myositis, myopathy, or rhabdomyolysis during the measurement year as evidenced through diagnosis code claims submission. <ul style="list-style-type: none"> - Most common codes to identify myopathy and myalgia: G72.0; G72.2; G72.9; M60.9; M62.82 - Documentation within the patient chart must be clear in stating myopathy or myalgia. Phrasing of “intolerance,” “reaction,” and “cannot take,” will not be evidence enough for an exclusion. Diagnosis for statin-caused myopathy or myalgia codes (as stated as such) that are documented within the allergy section of the patient chart are acceptable for denominator exclusion. • Pregnancy or in vitro fertilization during the measurement year or year prior. • Those without pharmacy benefits through Highmark. • Members 66 years of age and older as of December 31 of the measurement year with frailty AND advanced illness diagnoses (exclusions applied based on processed claims data only). • Members receiving palliative care (as defined by the HEDIS value sets) during the measurement year.

Topic	Explanation
Compliant Member	<p>Members who filled at least one ambulatory prescription for high or moderate intensity statin medication.</p> <p>Prescriptions filled under Highmark commercial plans will transition to numerator compliance for members who become newly enrolled in a Medicare Advantage Part D plan during the measurement year.</p>
How to Submit to Highmark Inc.	<p>Only one pharmacy claim is required. This measure is only captured via a pharmacy claim at the point of sale. Claims must adjudicate at the point of sale. Retrospective claims adjudication is not permissible.</p>
Best Practices	<ul style="list-style-type: none"> • Identify all patients who are non-compliant in measure. Reference monthly Stars Gap reports for the Statin measures tab for relevant information to aid in numerator compliance. • Ensure that provider prescribes appropriate medication and dosage. • Scour chart to identify any exclusions for this measurement year. New exclusion reports are posted to the User Interface which can assist to identify historical exclusions to consider. Exclusions for this measure need to be submitted each calendar year. • Submit exclusions via a claim for the diagnosis during an encounter or via an appropriate documentation through the CQF Loop. • Prep chart to ensure that provider discusses ongoing compliance. • Discuss with members the benefits of adhering to medication including nurses, physicians, medical assistants, and physician extenders. • Provide ongoing patient outreach to those showing as non-compliant. • Identify reason for non-compliance and attempt to resolve. • Consider statins with fewer drug interactions such as rosuvastatin, pravastatin, and fluvastatin to reduce risk of adverse events. • Patients who do not tolerate one statin may be able to tolerate a different statin. • Consider effective but low-cost treatment options that are on Tier 1 of the Highmark Medicare Part D formularies. • Utilize Highmark’s predesigned member letter templates and other informational resources that are located on the Provider Resource Center.
Other	<p>Encourage patients to utilize their insurance card, as this may help to identify other services that may be beneficial to them. Samples, paying in cash, and using discount cards will not generate an insurance claim. These patients will appear as non-compliant with the measure.</p>

Topic	Explanation									
Other (continued)	<p data-bbox="618 195 1211 222">High- and Moderate-Intensity Statin Medications</p> <table border="1" data-bbox="613 264 1450 856"> <thead> <tr> <th data-bbox="613 264 805 327">Description</th> <th colspan="2" data-bbox="805 264 1450 327">Prescription</th> </tr> </thead> <tbody> <tr> <td data-bbox="613 327 805 548">High-intensity statin therapy</td> <td data-bbox="805 327 1138 548"> <ul style="list-style-type: none"> • Atorvastatin 40–80 mg • Amlodipine-atorvastatin 40–80 mg </td> <td data-bbox="1138 327 1450 548"> <ul style="list-style-type: none"> • Rosuvastatin 20–40 mg • Simvastatin 80 mg • Ezetimibe-simvastatin 80 mg </td> </tr> <tr> <td data-bbox="613 548 805 856">Moderate-intensity statin therapy</td> <td data-bbox="805 548 1138 856"> <ul style="list-style-type: none"> • Atorvastatin 10–20 mg • Amlodipine-atorvastatin 10–20 mg • Rosuvastatin 5–10 mg • Simvastatin 20–40 mg • Ezetimibe-simvastatin 20–40 mg </td> <td data-bbox="1138 548 1450 856"> <ul style="list-style-type: none"> • Pravastatin 40–80 mg • Lovastatin 40 mg • Fluvastatin 40–80 mg • Pitavastatin 1–4 mg </td> </tr> </tbody> </table>	Description	Prescription		High-intensity statin therapy	<ul style="list-style-type: none"> • Atorvastatin 40–80 mg • Amlodipine-atorvastatin 40–80 mg 	<ul style="list-style-type: none"> • Rosuvastatin 20–40 mg • Simvastatin 80 mg • Ezetimibe-simvastatin 80 mg 	Moderate-intensity statin therapy	<ul style="list-style-type: none"> • Atorvastatin 10–20 mg • Amlodipine-atorvastatin 10–20 mg • Rosuvastatin 5–10 mg • Simvastatin 20–40 mg • Ezetimibe-simvastatin 20–40 mg 	<ul style="list-style-type: none"> • Pravastatin 40–80 mg • Lovastatin 40 mg • Fluvastatin 40–80 mg • Pitavastatin 1–4 mg
Description	Prescription									
High-intensity statin therapy	<ul style="list-style-type: none"> • Atorvastatin 40–80 mg • Amlodipine-atorvastatin 40–80 mg 	<ul style="list-style-type: none"> • Rosuvastatin 20–40 mg • Simvastatin 80 mg • Ezetimibe-simvastatin 80 mg 								
Moderate-intensity statin therapy	<ul style="list-style-type: none"> • Atorvastatin 10–20 mg • Amlodipine-atorvastatin 10–20 mg • Rosuvastatin 5–10 mg • Simvastatin 20–40 mg • Ezetimibe-simvastatin 20–40 mg 	<ul style="list-style-type: none"> • Pravastatin 40–80 mg • Lovastatin 40 mg • Fluvastatin 40–80 mg • Pitavastatin 1–4 mg 								

Key Additional Resources

Additional information specific to this measure can be found on the Provider Resource Center under **Value-Based Reimbursement Programs Overview**, in the **Medicare Advantage Stars** section.

Information on formulary medications and Utilization Management restrictions can be found in the **Pharmacy Program/Formularies** section on the Provider Resource Center.